SCHEMBL6235954

SCHEMBL6235954

O=C(O)CC1=Nc2ccc(O)cc2S(=O)(=O)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
PMP22 Q01453 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CAMK2A Q9UQM7 4/20 0.35
AKR1B1 P15121 2/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
GRB2 P62993 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6237565 0.84 CA2 (0.31) CA2CA12CA1CA4CA7
SCHEMBL6232214 0.84 CA2 (0.39) CA2CA12CA1CA4CA7
SCHEMBL6237560 0.81 CA12 (0.39) CA2CA12CA1CA4CA7
SCHEMBL3389367 0.69 ALDH1A1 (0.45) CA2CA12CA1CA4CA7
SCHEMBL3389375 0.66 CA2 (0.40) CA2CA12CA1CA4CA7
SCHEMBL20777719 0.63 CA1 (0.38) CA2CA12CA1CA4CA7
SCHEMBL30872945 0.63 CA12 (0.62) CA2CA12CA1CA4CA7
SCHEMBL9814710 0.63 CA12 (0.62) CA2CA12CA1CA4CA7
Ether SCHEMBL6234273 0.63 ALDH1A1 (0.42) CA2CA12CA1CA4CA7
SCHEMBL20777728 0.62 CA2 (0.36) CA2CA12CA1CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
WO-2004052313-A2 ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-06-24 WO disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CA2 4750/4885CA12 4222/4885CA1 4881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.